Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study — rationale,design,and methodological issues
Restricted accessOtherFirst published online October, 2007
Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study — rationale,design,and methodological issues
Background Depression is relatively common in patients with coronary heart disease (CHD) and is associated with worse prognosis. Recently there has been interest in evaluating the impact of treating depression on clinical outcomes. Anti-depressant medications have been shown to be safe and efficacious for many patients; exercise also may be effective for treating depression and may also improve cardiopulmonary functioning. However, methodological limitations of previous studies have raised questions about the value of exercise, and no study has compared the effects of exercise with standard anti-depressant medication in depressed cardiac patients.
Purpose UPBEAT is a randomized clinical trial (RCT) funded by NHLBI to evaluate the effects of sertraline or exercise compared to placebo on depression and biomarkers of cardiovascular risk in patients with CHD and elevated depressive symptoms.
Methods The UPBEAT study includes 200 stable CHD patients with scores on the Beck Depression Inventory (BDI) ≥9 randomized to 4 months of treatment with aerobic exercise, sertraline, or placebo. The primary outcomes include depressive symptoms determined by clinical ratings on the Hamilton Rating Scale for Depression (HAM-D) and measures of heart rate variability (HRV), baroreflex control (BRC), vascular function (i.e., flow-mediated dilation (FMD)), and measures of inflammation and platelet aggregation.
Results This article reviews the rationale and design of UPBEAT and addresses several key methodologic issues that were carefully considered in the development of this protocol: the use of a placebo control condition in depressed cardiac patients, study design, and selection of intermediate endpoints or biomarkers of cardiovascular risk.
Limitations This study is not powered to assess treatment group differences in CHD morbidity and mortality. Intermediate endpoints are not equivalent to `hard' clinical events and further studies are needed to determine the clinical significance of these biomarkers.
Conclusions The UPBEAT study is designed to assess the efficacy of exercise in treating depression in cardiac patients and evaluates the impact of treating depression on important biomarkers of cardiovascular risk. Clinical Trials 2007; 4: 548—559. http://ctj.sagepub.com
Get full access to this article
View all access options for this article.
References
1.
American Heart Association.2001. Heart and stroke statistical update. American Heart Association, Dallas, TX , 2001.
2.
Naghavi M. , Libby P. , Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I . Circulation2003; 108: 1664—72 .
3.
Naghavi M. , Libby P. , Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II . Circulation2003; 108: 1772—78 .
Carney RM , Freedland KE , Sheline YI , Weiss ESDepression and coronary heart disease: a review for cardiologists . Clin Cardiol1997; 20: 196—200 .
6.
Lett H. , Blumenthal J. , Babyak M. , Sherwood A. , Strauman T. , Robins C.Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment . Psychosom Med2004; 66: 305—15 .
7.
Rozanski A. , Blumenthal JA , Kaplan J.Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy . Circulation1999; 99: 2192—217 .
8.
Barth J. , Schumacher M. , Hermann-Lingen C.Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis . Psychosom Med2004 ; 66: 802—13 .
9.
van Melle JP , de Jong P. , Spijkerman TA et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta analysis . Psychosom Med2004; 66: 814—22 .
10.
Davidson KW , Rieckman N. , Lesperance F.Psychological theories of depression: potential application for the prevention of acute coronary syndrome recurrence . Psychosom Med2004; 66: 165—73 .
11.
Frasure-Smith N. , Lesperance F. , Talajic M.Depression following myocardial infarction: impact on 6-month survival . JAMA1993; 270: 1819—25 .
12.
Frasure-Smith N. , Lesperance F. , Talajic M.Depression and 18-month prognosis after myocardial infarction . Circulation1995; 91: 999—1005 .
13.
Frasure-Smith N. , Lesperance F. , Juneau M. , Talajic M. , Bourassa MGGender, depression, and one-year prognosis after myocardial infarction . Psychosom Med1999; 61: 26—37 .
14.
Lesperance F. , Frasure-Smith N. , Talajic M. , Bourassa MGFive-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction . Circulation2002; 105: 1049—53 .
15.
Bush DE , Ziegelstein RC , Tayback M. et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction . Am J Cardiol2001; 88: 337—41 .
16.
Anderson RJ , Freedland KE , Clouse RE , Lustman PJThe prevalence of comorbid depression in adults with diabetes: a meta-analysis . Diabetes Care2001; 24: 1069—78 .
17.
Thakore JH , Richards PJ , Reznek RH , Martin A. , Dinan TGIncreased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. BiologicalPsychiatry1997; 41: 1140—42 .
18.
Rich MW , Saini JS , Kleiger RE , Carney RM , Tevelde A. , Freedland KECorrelation of heart rate variability with clinical and angiographic variables and late mortality after coronary angiography . Am J Cardiol1988; 62: 1—7 .
19.
Kleiger RE , Miller JP , Bigger Jr, JT , Moss AJDecreased heart rate variability and its association with increased mortality after acute myocardial infarction . Am J Cardiol1987; 59: 256—62 .
20.
Nolan J. , Batin PD , Andrews R. et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart) . Circulation1998; 98: 1510—16 .
21.
Carney RM , Saunders RD , Freedland KE , Stein P. , Rich MW , Jaffe ASAssociation of depression with reduced heart rate variability in coronary artery disease . Am J Cardiol1995; 76: 562—64 .
22.
Carney RM , Blumenthal JA , Stein PK et al. Depression, heart rate variability, and acute myocardial infarction . Circulation2001; 104: 2024—28 .
23.
Casolo G. , Balli E. , Taddei T. , Amuhasi J. , Gori C.Decreased spontaneous heart rate variability in congestive heart failure . Am J Cardiol1989; 64: 1162—67 .
24.
Watkins LL , Grossman P.Association of depressive symptoms with reduced baroreflex cardiac control in coronary artery disease . Am Heart J1999 ; 137: 453—57 .
25.
La Rovere MT , Bersano C. , Gnemmi M. , Specchia G. , Schwartz PJExercise-induced increase in baroreflex sensitivity predicts improved prognosis after myocardial infarction . Circulation2002; 106: 945—49 .
26.
Hohnloser SH , Klingenheben T. , van de LA , Hablawetz E. , Just H. , Schwartz PJReflex versus tonic vagal activity as a prognostic parameter in patients with sustained ventricular tachycardia or ventricular fibrillation . Circulation1994; 89: 1068—73 .
27.
De Ferrari GM , Landolina M. , Mantica M. , Manfredini R. , Schwartz PJ , Lotto A.Baroreflex sensitivity, but not heart rate variability, is reduced in patients with life-threatening ventricular arrhythmias long after myocardial infarction . Am Heart J1995; 130: 473—80 .
28.
Billman GE , Schwartz PJ , Stone HLBaroreceptor reflex control of heart rate: a predictor of sudden cardiac death . Circulation1982; 66: 874—80 .
29.
Kennedy GJ , Hofer MA , Cohen D. , Shindledecker R. , Fisher JDSignificance of depression and cognitive impairment in patients undergoing programed stimulation of cardiac arrhythmias . Psychosom Med1987; 49: 410—21 .
30.
Brevetti G. , Silvestro A. , Schiano V. , Chiariello M.Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index . Circulation2003; 108: 2093—98 .
31.
Bonetti PO , Lerman LO , Lerman A.Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis & VascularBiology2003; 23: 168—75 .
32.
Rajagopalan S. , Brook R. , Rubenfire M. , Pitt E. , Young E. , Pitt B.Abnormal brachial artery flow-mediated vasodilation in young adults with major depression . Am J Cardiol2001; 88: 196—98 .
33.
Broadley AJ , Korszun A. , Jones CJ , Frenneaux MPArterial endothelial function is impaired in treated depression . Heart (British Cardiac Society)2002; 88: 521—23 .
34.
Harris KF , Matthews KA , Sutton-Tyrrell K. , Kuller LHAssociations between psychological traits and endothelial function in postmenopausal women . Psychosom Med2003; 65: 402—09 .
35.
Sherwood A. , Hinderliter AL , Watkins LL , Waugh RA , Blumenthal JAImpaired endothelial function in coronary heart disease patients with depressive symptomatology . JACC2005; 46: 656—59 .
Ridker PM , Rifai N. , Rose L. , Buring JE , Cook NRComparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events . NEJM2002; 347: 1557—65 .
38.
Tall ARC-reactive protein reassessed . NEJM2004; 350: 1450—52 .
39.
Ford DE , Erlinger TPDepression and C-reative protein in US adults . Arch Intern Med2004; 164: 1010—14 .
40.
Patrono C. , Renda G.Platelet activation and inhibition in unstable coronary syndromes . Am J Cardiol1997; 80: 17E—20E .
41.
Thaulow E. , Erikssen J. , Sandvik L. , Stormorken H. , Cohn PFBlood platelet count and function are related to total and cardiovascular death in apparently healthy men . Circulation1991; 84: 613—17 .
42.
Markovitz JH , Shuster JL , Chitwood WS , May RS , Tolbert LCPlatelet activation in depression and effects of sertraline treatment: an open-label study . Am J Psychiat2000; 157: 1006—08 .
43.
Musselman DL , Tomer A. , Manatunga AK et al. Exaggerated platelet reactivity in major depression . Am J Psychiat1996; 153: 1313—17 .
44.
Kop WJ , Gottdiener JS , Tangen CM et al. Inflammation and coagulation factors in persons >65 years of age with symptoms of depression but without evidence of myocardial ischemia . Am J Cardiol2002; 89: 419—24 .
45.
Laghrissi-Thode F. , Wagner WR , Pollock BG , Johnson PC , Finkel MSElevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. BiologicalPsychiatry1997; 42: 290—95 .
46.
Depression Guideline Panel.Depression in Primary Care, Volume 2. Treatment of Depression, Clinical Practice Guideline, No. 5. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, HHCPR , 1993.
47.
Lesperance F. , Frasure-Smith N. , Koszycki D. et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) Trial . JAMA2007; 297: 367—79 .
48.
Glassman AH , O'Connor CM , Califf RM et al. Sertraline treatment of major depression in patients with acute MI or unstable angina . JAMA2002; 288: 701—09 .
49.
Writing Committee for the ENRICHD Investigators.Effects of treating depression and low perceived social support on clinical events after myocardial infarction . JAMA2003; 289: 3106—16 .
50.
Taylor CB , Youngblood ME , Catellier D. et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction . Arch Gen Psychiatry2005; 62: 792—98 .
51.
Sherwood A. , Blumenthal JA , Trivedi R. et al. Relationship of depression to death or hospitalization in patients with heart failure . Arch Int Med2007; 167: 367—73 .
52.
Carney RM , Blumenthal JA , Freedland KE et al. Depression and late mortality after myocardial infarction in the enhancing recovery in coronary heart disease (ENRICHD) Study . Psychosom Med2004; 66: 466—74 .
53.
Brosse AL , Sheets ES , Lett HS , Blumenthal JAExercise and the treatment of clinical depression in adults: recent findings and future directions . Sports Medicine2002 ; 32: 741—60 .
54.
Folkins CH , Sime WEPhysical fitness training and mental health . Am Psychologist1981; 36: 373—89 .
55.
Hughes JRPsychological effects of habitual aerobic exercise: a critical review . Prev Med1984; 13: 66—78 .
56.
Greist JH , Klein M.Running as a treatment for depression . Comp Psychiat1979; 20: 41—54 .
57.
Lawlor DA , Hopker SWThe effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials . Br Med J2001; 322: 763—67 .
58.
Blumenthal JA , Babyak MA , Moore KA et al. Effects of exercise training on older patients with major depression . Arch Int Med1999; 159: 2349—56 .
59.
Dunn AL , Trivedi MH , Kampert JB , Clark CG , Chambliss HOExercise treatment for depression: Efficacy and dose response . Am J Prev Med2005; 28: 1—8 .
60.
Blumenthal JA , Babyak MA , Carney RM et al. Exercise, depression, and mortality after myocardial infarction in the ENRICHD trial . Medicine and Science in Sports and Exercise2004; 36: 746—55 .
61.
Bigger Jr, JT , Albrecht P. , Steinman RC , Rolnitzky LM , Fleiss JL , Cohen RJComparison of time- and frequency domain-based measures of cardiac parasympathetic activity in Holter recordings after myocardial infarction . Am J Cardiol1989; 64: 536—38 .
62.
BiggerJr. JT, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction . Circulation1992; 85: 164—71 .
63.
Welch PDThe use of fast Fourier transform for the estimation of power spectra: a method based on time averaging over short modified periodograms . IEEE Trans Audio Electroacoust1967; 15: 70—73 .
64.
Celermajer DS , Sorensen KE , Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis . Lancet1992; 340: 1111—15 .
65.
Corretti MC , Anderson TJ , Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task . JACC2002; 39: 257—65 .
66.
Celermajer DS , Sorensen KE , Bull C. , Robinson J. , Deanfield JEEndothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction . JACC1994; 24: 1468—74 .
67.
Kuipers PM , Hamauluak K.β Thromboglobulin and platelet factor 4 levels in post-MI patients with major depression . Psychiat Res2002; 109: 207—10 .
68.
Martinez-Sales V. , Vila V. , Reganon E. , Goberna MA et al. Elevated thrombotic activity after myocardial infarction: a 2-year follow-up study . Haemostasis1998; 28: 301—6 .
69.
Serebruany VL , Glassman AH , Malinin AI et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy . Circulation2003; 108: 939—44 .
70.
Muthen B.A general structural equation model with dichotomous, ordered categorical, and continuous latent variable indicators . Psychometrika1984; 49: 115—32 .
71.
Blumenthal JA , Sherwood A. , Babyak MA et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease; a randomized controlled trial . JAMA2005; 293(13): 1626—34 .
72.
Benjamini Y. , Hochberg Y.Controlling the false discovery rate: a practical and powerful approach to multiple testing . J Royal Stat Soc , Series B 1995; 57: 289—300 .
73.
Levine R.The use of placebos in randomized clinical trials . IRB1985; 7: 1—4 .
74.
Rothman KJ , Michels KBThe continuing unethical use of placebo controls . NEJM1994; 331: 394—8 .
75.
Addington D. , Williams R. , Lapierre Y. , el Guebaly N.Placebos in clinical trials of psychotropic medication . Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie1997; 42: 1—6 .
76.
Bialik RJ , Ravindran AV , Bakish D. , Lapierre YDA comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiat &Neurosci1995; 20: 265—70 .
77.
Klein DFPreventing hung juries about therapy studies. J Consult &Clin Psychol1996; 64: 81—87 .
78.
Klerman GLScientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology . Psychopharmacol Bull1986; 22: 25—29 .
79.
Prien RFMethod and models for placebo use in pharmacotherapeutic trials . Psychopharmacol Bull1988; 24: 4—8 .
80.
Temple R.Difficulties in evaluating positive control trials . Clinic Eval1993; 21: 141—149 .
81.
Rozanski A. , Blumenthal JA , Davidson KW , Saab PG , Kubzansky L.The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice . JACC2005; 45: 637—51 .
